3-(2-AMINOETHYL)INDOL-5-OL CREATININE SULFATE cas no:971-74-4

Name3-(2-AMINOETHYL)INDOL-5-OL CREATININE SULFATE
CAS971-74-4
Synonyms3-(2-aminoethyl)-indol-5-ocompd.withcreatininesulfate;3-(2-aminoethyl)indol-5-ol,creatininesulfate;5-htcreatininesulfate;creatinine,sulfate,compd.with3-(2-aminoethyl)indol-5-ol(1:1:1);creatinine,sulfate,compd.with3-(2-aminoethyl)indole-5-ol(1:1:1),monohyd;serotincreatininesulfate;5-HYDROXYTRYPTAMINE CREATININE SULFATE;5-HYDROXYTRYPTAMINE CREATININE SULFATE COMPLEX
EINECS(EC#)213-539-3
Molecular FormulaC10H12N2O . C4H7N3O . H2O4S . H2O
Molecular Weight387.41

storage temp2-8°C

Hazard Xn
Risk 63-20/21/22
Safety

Poison by subcutaneous and intravenous routes. Moderately toxic by intraperitoneal route. An experimental teratogen. Other experimental reproductive effects. See also SULFATES. When heated to decomposition it emits very toxic fumes of SO_x and NO_x.
Hazard Codes of 5-Hydroxytryptamine creatinine sulfate (CAS NO.971-74-4): Xn
Risk Statements: 63-20/21/22 
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed. 
R63:Possible risk of harm to the unborn child.
Safety Statements: 36/37-24/25-22 
S22:Do not breathe dust. 
S24/25:Avoid contact with skin and eyes. 
S36/37:Wear suitable protective clothing and gloves.

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
guinea pig	LD50	intravenous	28mg/kg (28mg/kg)	LUNGS, THORAX, OR RESPIRATION: BRONCHIOLAR CONSTRICTION	Journal of Pharmaceutical Sciences. Vol. 57, Pg. 1543, 1968.
mouse	LD50	intraperitoneal	405mg/kg (405mg/kg)		Yakugaku Zasshi. Journal of Pharmacy. Vol. 94, Pg. 1620, 1974.
mouse	LD50	intravenous	352mg/kg (352mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 105, Pg. 80, 1952.
mouse	LD50	subcutaneous	> 1997mg/kg (1997mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 105, Pg. 80, 1952.
rat	LD50	intravenous	66mg/kg (66mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 105, Pg. 80, 1952.
rat	LD50	subcutaneous	257mg/kg (257mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 105, Pg. 80, 1952.